ES2630905T3 - Proteínas inmunitarias innatas como biomarcadores para lesiones del SNC - Google Patents

Proteínas inmunitarias innatas como biomarcadores para lesiones del SNC Download PDF

Info

Publication number
ES2630905T3
ES2630905T3 ES13746979.7T ES13746979T ES2630905T3 ES 2630905 T3 ES2630905 T3 ES 2630905T3 ES 13746979 T ES13746979 T ES 13746979T ES 2630905 T3 ES2630905 T3 ES 2630905T3
Authority
ES
Spain
Prior art keywords
patient
protein
injury
inflamasome
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13746979.7T
Other languages
English (en)
Spanish (es)
Inventor
Robert W. Keane
W. Dalton Dietrich
Juan Pablo De Rivero Vaccari
Stephanie ADAMCZAK
M. Ross Bullock
Allan LEVI
Michael Y. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Application granted granted Critical
Publication of ES2630905T3 publication Critical patent/ES2630905T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES13746979.7T 2012-02-06 2013-02-06 Proteínas inmunitarias innatas como biomarcadores para lesiones del SNC Active ES2630905T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595254P 2012-02-06 2012-02-06
US201261595254P 2012-02-06
PCT/US2013/024941 WO2013119673A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury

Publications (1)

Publication Number Publication Date
ES2630905T3 true ES2630905T3 (es) 2017-08-25

Family

ID=48947960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13746979.7T Active ES2630905T3 (es) 2012-02-06 2013-02-06 Proteínas inmunitarias innatas como biomarcadores para lesiones del SNC

Country Status (6)

Country Link
US (4) US20150185232A1 (https=)
EP (1) EP2812697B1 (https=)
JP (1) JP6170071B2 (https=)
CA (1) CA2863417C (https=)
ES (1) ES2630905T3 (https=)
WO (1) WO2013119673A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2015157390A1 (en) * 2014-04-08 2015-10-15 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3562506A4 (en) 2016-12-29 2021-01-06 University of Miami METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
KR101910269B1 (ko) * 2017-02-24 2018-10-19 성균관대학교산학협력단 인간 뇌 조직 유래 신경줄기세포의 고효율 분리 방법
BR112020005445A2 (pt) * 2017-09-20 2020-09-29 University Of Miami método para a detecção de proteínas do inflamassoma como biomarcadores de transtornos neurológicos
WO2019199869A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in physiological samples
WO2020010273A1 (en) 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
EP3918336A1 (en) * 2019-01-31 2021-12-08 University of Geneva Prospective markers in traumatic brain injury (tbi)
WO2021071934A1 (en) * 2019-10-07 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Polymeric methylprednisolone conjugates and uses thereof
CA3176521A1 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022156A2 (en) * 2002-09-04 2004-03-18 Washington University Methods for treating central nervous system damage
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CN101983337A (zh) * 2008-02-04 2011-03-02 班扬生物标记公司 用于诊断或治疗脑损伤的方法
US8404752B2 (en) * 2008-07-18 2013-03-26 Oxygen Biotherapeutics, Inc. Method of treating traumatic brain injury
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Also Published As

Publication number Publication date
US20200363432A1 (en) 2020-11-19
EP2812697A1 (en) 2014-12-17
US20230349929A1 (en) 2023-11-02
US12560618B2 (en) 2026-02-24
CA2863417A1 (en) 2013-08-15
CA2863417C (en) 2020-07-28
EP2812697B1 (en) 2017-03-22
WO2013119673A1 (en) 2013-08-15
EP2812697A4 (en) 2015-08-26
JP2015508887A (ja) 2015-03-23
JP6170071B2 (ja) 2017-07-26
US20170003303A1 (en) 2017-01-05
US20150185232A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
ES2630905T3 (es) Proteínas inmunitarias innatas como biomarcadores para lesiones del SNC
Hulme et al. The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
KR20200088299A (ko) 신경학적 장애의 바이오마커로서 인플라마솜 단백질의 검출 방법
Stejskal et al. DETERMINATION OF SERUM VISININ LIKE PROTEIN-1 AND ITS POTENTIAL FOR THE DIAGNOSIS OF BRAIN INJURY DUE TO THE STROKE-A PILOT STUDY.
Banks et al. Assessing blood granulocyte colony-stimulating factor as a potential biomarker of acute traumatic brain injury in mice and humans
Diniz et al. Premature aging in serious mental illness
US20240060995A1 (en) Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
Shaker et al. Serum levels of S100b, interleukin-6 and anti-transglutaminase Ii IgA as immune markers in a sample of Egyptian children with autistic spectrum disorders
Tang et al. Integrative multi-omics and machine learning identify CALR as a diagnostic and therapeutic target in aneurysmal subarachnoid hemorrhage
Choi et al. Enhanced apoptotic activity in allergic diseases and its relationship with eosinophil cationic protein, systemic inflammation, and severity of atopic sensitisation
US20200057078A1 (en) Melanotransferrin for use in the diagnosis of parkinson`s disease
Ji et al. Baseline S100B protein as a potential predicator for postoperative cognitive dysfunction in elderly patients after hip joint replacement surgery
WO2023212583A9 (en) Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
Ozturk et al. The relationship between serum prolidase activity and histone H3 protein levels and fibromyalgia.
KR102953162B1 (ko) 신경학적 장애의 바이오마커로서 인플라마솜 단백질의 검출 방법
Kheiruralla et al. Evaluation of serum pro-inflammatory cytokines (TNF and IL-6) in patients with giardiasis
Li et al. Correlation between NLRP6 inflammasome and the levels of inflammatory cytokines IL-1b and IL-18 in serum of patients with Meniere's disease
Alqarni Effect of cigarette smoke extract on allergen and viral responses in human bronchial epithelial cells
Elshafey et al. Evaluation of the Relationship between Pemphigus Vulgaris Severity and the Serum Levels of IL33 and anti-Desmoglein-3 Antibody
TWI521204B (zh) 阿茲海默症之分子指標
Anczykowski et al. The reference level of serum S-100B protein for poor prognosis in patients with intracranial extracerebral hematoma
WO2022214717A1 (es) Biomarcador en líquido cefalorraquídeo para enfermedad de alzheimer
Haque Salivary Huntingtin in Huntington's Disease
Blackney Evaluating Evolving Leukocyte Populations In Peripheral Blood Circulation Post-Concussion In A Human Longitudinal Analysis Of Female Athletes